Cue Biopharma (Cue Biopharma) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Cue Biopharma Days Payable?

Cue Biopharma's average Accounts Payable for the three months ended in Dec. 2023 was $2.99 Mil. Cue Biopharma's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.00 Mil.

The historical rank and industry rank for Cue Biopharma's Days Payable or its related term are showing as below:

CUE's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 152.29
* Ranked among companies with meaningful Days Payable only.

Cue Biopharma's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00). stayed the same

Cue Biopharma Days Payable Historical Data

The historical data trend for Cue Biopharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma Days Payable Chart

Cue Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

Cue Biopharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cue Biopharma's Days Payable

For the Biotechnology subindustry, Cue Biopharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cue Biopharma's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cue Biopharma's Days Payable distribution charts can be found below:

* The bar in red indicates where Cue Biopharma's Days Payable falls into.

Cue Biopharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Cue Biopharma's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (2.731	+	3.501)	/	2 )	/	0	*	365
=	3.116					/	0	*	365
=	N/A

Cue Biopharma's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (2.48	+	3.501)	/	2 )	/	0	*	365 / 4
=	2.9905					/	0	*	365 / 4
=	N/A

Cue Biopharma Days Payable Related Terms

Thank you for viewing the detailed overview of Cue Biopharma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Cue Biopharma (Cue Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (NAS:CUE) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

1UC:Germany 1UC:Germany

Address

40 Guest Street, Boston, MA, USA, 02135

Website

https://www.cuebiopharma.com

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.

Executives

Anish Suri	officer: President and CSO	40 GUEST STREET, BOSTON MA 02135
Daniel R Passeri	director, officer: CEO	40 GUEST STREET, BOSTON MA 02135
Pamela Garzone	director	C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Patrick Verheyen	director	C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Peter A Kiener	director	40 GUEST STREET, BOSTON MA 02135
Matteo Levisetti	officer: Chief Medical Officer	C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Frank Morich	director	40 GUEST STREET, BOSTON MA 02135
Fletcher Aaron G.l.	director	40 GUEST STREET, BOSTON MA 02135
Patricia Nasshorn	officer: Chief Business Officer	C/O WOMEN FIRST HEALTHCARE INC, 12220 EL CAMINO REAL, SAN DIEGO CA 92130
Kerri-ann Millar	officer: CFO	40 GUEST STREET, BOSTON MA 02135
Kenneth Pienta	officer: Chief Medical Officer	C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Sandercock Colin	officer: SVP, General Counsel and Sec	40 GUEST STREET, BOSTON MA 02135
Tamar D Howson	director
Barry J. Simon	director	2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
Frederick W Driscoll	director